Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Published:2021-12 Issue:12 Volume:8 Page:e912-e921
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Eyre Toby A,Schuh Anna,Wierda William G,Brown Jennifer R,Ghia Paolo,Pagel John M,Furman Richard R,Cheung Jean,Hamdy Ahmed,Izumi Raquel,Patel Priti,Wang Min Hui,Xu Yan,Byrd John C,Hillmen Peter

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Epidemiological patterns of leukaemia in 184 countries: a population-based study;Miranda-Filho;Lancet Haematol,2018

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

3. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2016

4. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia;Roberts;N Engl J Med,2016

5. Ibrutinib and venetoclax for first-line treatment of CLL;Jain;N Engl J Med,2019

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

2. Overcoming the unmet need of Richter transformation: the use of pirtobrutinib;The Lancet Haematology;2024-09

3. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

4. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study;The Lancet Haematology;2024-09

5. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07